Impact of PD-L1 feedback modulation on the sensitivity of anti-PD-1/PD-L1

被引：0
|
作者：
Zhu, Jian [1 ]
Zhu, Rebecca L. [2 ]
机构：
[1] OmicsHealth LLC, Potomac, MD USA
[2] Winston Churchill High Sch, Potomac, MD USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
673
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pneumonitis with anti-PD-1/PD-L1 therapy
    Naidoo, J.
    Cunningham, J.
    Woo, K. M.
    Hellmann, M. D.
    Postow, M. A.
    Drilon, A. E.
    Chaft, J. E.
    Lesokhin, A. M.
    Segal, N. H.
    Callahan, M. K.
    Rudin, C. M.
    Iyriboz, T.
    Wolchok, J. D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
  • [2] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
    Sui, Xinbing
    Ma, Junhong
    Han, Weidong
    Wang, Xian
    Fang, Yong
    Li, Da
    Pan, Hongming
    Zhang, Li
    [J]. ONCOTARGET, 2015, 6 (23) : 19393 - 19404
  • [3] High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
    Sanchez-Magraner, Lissete
    Miles, James
    Baker, Claire L.
    Applebee, Christopher J.
    Lee, Dae-Jin
    Elsheikh, Somaia
    Lashin, Shaimaa
    Withers, Katriona
    Watts, Andrew G.
    Parry, Richard
    Edmead, Christine
    Lopez, Jose Ignacio
    Mehta, Raj
    Italiano, Antoine
    Ward, Stephen G.
    Parker, Peter J.
    Larijani, Banafshe
    [J]. CANCER RESEARCH, 2020, 80 (19) : 4244 - 4257
  • [4] Pneumonitis From Anti-PD-1/PD-L1 Therapy
    Balaji, Aanika
    Verde, Franco
    Suresh, Karthik
    Naidoo, Jarushka
    [J]. ONCOLOGY-NEW YORK, 2017, 31 (10): : 739 - +
  • [5] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Festino, Lucia
    Botti, Gerardo
    Lorigan, Paul
    Masucci, Giuseppe V.
    Hipp, Jason D.
    Horak, Christine E.
    Melero, Ignacio
    Ascierto, Paolo A.
    [J]. DRUGS, 2016, 76 (09) : 925 - 945
  • [6] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
    Lucia Festino
    Gerardo Botti
    Paul Lorigan
    Giuseppe V. Masucci
    Jason D. Hipp
    Christine E. Horak
    Ignacio Melero
    Paolo A. Ascierto
    [J]. Drugs, 2016, 76 : 925 - 945
  • [7] Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
    Kudo, Masatoshi
    [J]. LIVER CANCER, 2020, 9 (06) : 629 - 639
  • [8] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    [J]. EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [9] The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer
    James Randall Patrinely
    Anna K. Dewan
    Douglas B. Johnson
    [J]. BioDrugs, 2020, 34 : 495 - 503
  • [10] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Mengke Niu
    Ming Yi
    Ning Li
    Suxia Luo
    Kongming Wu
    [J]. Experimental Hematology & Oncology, 10
12345